Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 215

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 215
---
48 Granted172,725 $33.50 Vested(137,923)$32.31 Forfeited(15,424)$32.47 Nonvested, September 30, 2025 (unaudited)397,543 $32.98 

27

Performance Share Units The following table summarizes performance share unit (PSU) activities:Performance-Based UnitsMarket-Based UnitsTotal PSUs Number of PSUsWeightedAverageGrant Date Fair Value per ShareNumber of PSUsWeightedAverageGrant Date Fair Value per ShareNumber of PSUsWeightedAverageGrant Date Fair Value per ShareNonvested, December 31, 2024324,685 $28.80 20,000 $28.63 344,685 $28.79 Granted246,496 $32.84 — $— 246,496 $32.84 Vested(138,510)$29.96 (20,000)$28.63 (158,510)$29.79 Forfeited(38,800)$30.31 — $— (38,800)$30.31 Nonvested, September 30, 2025 (unaudited)393,871$30.77 — $— 393,871$30.77 

11.    Earnings (Loss) per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2025 and 2024 (dollars in thousands, except share and per share amounts):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)Numerator:Net earnings (loss)$(45,117)$38,497 $(34,445)$58,537 Denominator:Weighted average shares outstanding, basic56,552,741 55,149,760 56,133,918 54,977,199 Effect of dilutive securities:Stock options and stock awards— 866,590 — 813,986 Weighted average shares outstanding, diluted56,552,741 56,016,350 56,133,918 55,791,185 Earnings (loss) per share, basic$(0.80)$0.70 $(0.61)$1.06 Earnings (loss